JP2022502380A - 抗ｃｄ１５４抗体の安全な投与を提供する方法 - Google Patents

抗ｃｄ１５４抗体の安全な投与を提供する方法 Download PDF

Info

Publication number
JP2022502380A
JP2022502380A JP2021516643A JP2021516643A JP2022502380A JP 2022502380 A JP2022502380 A JP 2022502380A JP 2021516643 A JP2021516643 A JP 2021516643A JP 2021516643 A JP2021516643 A JP 2021516643A JP 2022502380 A JP2022502380 A JP 2022502380A
Authority
JP
Japan
Prior art keywords
antibody
antigen
binding fragment
administration
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021516643A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022502380A5 (https=
JPWO2020068723A5 (https=
Inventor
リグビー，マーク
レブレ，ドナルド
パイアントーン，アレクサ
レウ，ジョセリン
サビンス，ニナ，チ
Original Assignee
ヤンセン バイオテツク，インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン バイオテツク，インコーポレーテツド filed Critical ヤンセン バイオテツク，インコーポレーテツド
Publication of JP2022502380A publication Critical patent/JP2022502380A/ja
Publication of JP2022502380A5 publication Critical patent/JP2022502380A5/ja
Publication of JPWO2020068723A5 publication Critical patent/JPWO2020068723A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2021516643A 2018-09-24 2019-09-24 抗ｃｄ１５４抗体の安全な投与を提供する方法 Withdrawn JP2022502380A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862735529P 2018-09-24 2018-09-24
US62/735,529 2018-09-24
US201962826131P 2019-03-29 2019-03-29
US62/826,131 2019-03-29
PCT/US2019/052558 WO2020068723A1 (en) 2018-09-24 2019-09-24 Method of providing safe administration of an anti-cd154 antibody

Publications (3)

Publication Number Publication Date
JP2022502380A true JP2022502380A (ja) 2022-01-11
JP2022502380A5 JP2022502380A5 (https=) 2022-10-03
JPWO2020068723A5 JPWO2020068723A5 (https=) 2022-10-03

Family

ID=69950835

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021516643A Withdrawn JP2022502380A (ja) 2018-09-24 2019-09-24 抗ｃｄ１５４抗体の安全な投与を提供する方法

Country Status (6)

Country Link
US (1) US20210317220A1 (https=)
EP (1) EP3856246A4 (https=)
JP (1) JP2022502380A (https=)
CN (1) CN112770774A (https=)
AU (1) AU2019347730A1 (https=)
WO (1) WO2020068723A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115812080A (zh) * 2020-07-08 2023-03-17 瑞泽恩制药公司 含有抗ctla-4抗体的稳定调配物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2682292A1 (en) * 2007-03-30 2008-10-09 Medimmune, Llc Aqueous formulation comprising an anti-human interferon alpha antibody
GB0718684D0 (en) * 2007-09-24 2007-10-31 Roche Products Ltd Treatment method
US9028826B2 (en) * 2011-04-04 2015-05-12 The Trustees Of Dartmouth College Methods of immune therapy with anti-CD154 antibodies having impaired FcR binding and/or complement binding properties
AU2012323316B2 (en) * 2011-10-11 2017-08-10 Viela Bio, Inc. CD40L-specific Tn3-derived scaffolds and methods of use thereof
GB201501613D0 (en) * 2015-01-30 2015-03-18 Ucb Biopharma Sprl Treatment of autoimmune disorders with CD154 antibodies
IL256800B2 (en) * 2015-07-14 2023-04-01 Immunext Inc An anti-cd154 antibody with improved binding, functional and safety properties and use in human immunotherapy
PE20180802A1 (es) * 2015-08-05 2018-05-09 Janssen Biotech Inc Anticuerpos anti-cd154 y metodos de uso de estos

Also Published As

Publication number Publication date
CN112770774A (zh) 2021-05-07
WO2020068723A1 (en) 2020-04-02
US20210317220A1 (en) 2021-10-14
EP3856246A4 (en) 2022-07-20
EP3856246A1 (en) 2021-08-04
AU2019347730A1 (en) 2021-03-25

Similar Documents

Publication Publication Date Title
JP7775347B2 (ja) 癌治療におけるｆｇｆｒ２阻害剤単独または免疫刺激剤との組み合わせ
Stohl Future prospects in biologic therapy for systemic lupus erythematosus
EP2433650A2 (en) Administration of anti-CD3 antibodies in the treatment of autoimmune diseases
US20170247455A1 (en) Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody
RU2746314C2 (ru) Антитела анти-tnfrsf25
US20130315913A1 (en) Anti-light antibody therapy for inflammatory bowel disease
JP2019506403A (ja) がんを処置するためのｏｘ４０アゴニストおよび４−１ｂｂアゴニストモノクローナル抗体の組み合わせ
KR20110126740A (ko) 항-ｂｃｍａ 항체
KR20210077725A (ko) 항-cd38 항체의 피하 투여를 제공하는 방법
KR20140008305A (ko) Ｉｌ-１７ 길항제를 사용한 류마티스성 관절염의 치료 방법
JP2022116272A (ja) Ｔ１ｄｍ及び膵島炎の治療に使用するための抗ｃｄ４０抗体
KR20170062505A (ko) Cd28에 대해 지시된 도메인 항체를 사용하여 전신성 홍반성 루푸스를 치료하는 방법
KR20200033225A (ko) C5-관련 질환의 치료 또는 예방용 의약 조성물 및 c5-관련 질환을 치료 또는 예방하기 위한 방법
US11851497B2 (en) CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
KR20240099362A (ko) 혈액암에 대한 lag-3 길항제 요법
JP2022502380A (ja) 抗ｃｄ１５４抗体の安全な投与を提供する方法
AU2021352981A1 (en) Anti-cd94 antibodies and methods of use thereof
JP2022534494A (ja) 抗ｃｄ４０抗体の安全な投与を提供する方法
HK40050403A (en) Method of providing safe administration of an anti-cd154 antibody
JP2020517648A (ja) 抗ｃｄ５２抗体を用いて多発性硬化症を処置するための経路およびスケジュール
US20240025987A1 (en) Use of anti-il-27 antibodies
EP4531916A1 (en) Antibody compositions and methods of use thereof
HK40120413A (zh) 用於治疗igg4相关疾病的方法和组合物
HK40067213A (zh) 提供抗cd40抗体的安全施用的方法
KR20210021153A (ko) 류마티스 관절염에 대한 치료

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220922

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220922

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230623

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20230713